Where Knowledge is Created and Shared
Yale Pathology

Molecular Diagnostics Laboratory
203-785-4492
pathmdx@yale.edu

Molecular Diagnostics Requisition

MD Requesting Test: _____

Responsible Institution: _____

Date requested: _____/_____/_____

Tel: _____ **Fax:** _____

Patient name: _____

Date of birth: _____/_____/_____

Pathology No: _____

Pathology barcode

Clinical history and provisional diagnosis:

Tissue source: _____ **Date requested:** _____/_____/_____ **Date received:** _____/_____/

_____ **Tissue Preparation:** ☐ Paraffin (part# _____block# _____)

Tissue/Specimen Preparation

Fresh or Frozen Tissue: Please call the lab for instructions.

Fixed Tissue: Paraffin block(s) or ten unstained sections 5 µm thick (on charged slides if FISH analysis is ordered) or more, depending on tissue volume. Submission of acid-decalicified tissue specimen is discouraged.

Please check the box(es) for test(s) requested:

PCR Tests

- ☐ ***BRAF* mutation testing (exon 15)**
  (Thyroid carcinoma, hairy cell leukemia and other solid tumors)
- ☐ **DNA extraction**
- ☐ ***FOXL2* mutation testing (exon 1)**
  (Granulosa cell tumor and other ovarian neoplasms)
- ☐ **Immunoglobulin heavy chain gene rearrangement/Clonality analysis** (B cell lymphoma)
- ☐ ***KIT (c-Kit)* mutation testing (exons 9, 11, 13, 17, 18)**
  (GIST, melanoma and other solid tumors)
- ☐ ***KRAS* mutation testing (exon 2)**
  (Solid tumors and precancerous lesions)
- ☐ ***MGMT* promoter DNA methylation**
  (Gliomas)
- ☐ ***MLH1* methylation**
  (Screening tool for Lynch syndrome)
- ☐ **Microsatellite instability analysis (MSI)**
  (HHPCC/Lynch syndrome)
- ☐ ***Mycobacterium tuberculosis***
  (TB infection)
- ☐ **T-cell receptor gene rearrangement/Clonality analysis**
  (T cell lymphoma)
- ☐ ***Archer FusionPlex***
  (PCR/NGS RNA fusions in solid tumors)
- ☐ **ThyroSure Gene Panel**
  (PCR/NGS for thyroid carcinoma)
- ☐ **Tissue DNA fingerprinting/Genotyping**
  (Identity testing and hydatidiform moles)

FISH Tests

- ☐ ***CCND1 (BCL1)* gene rearrangement/translocation t(11;14)**
  (Mantle cell lymphoma)
- ☐ ***CDKN2A* deletion**
  (mesothelioma, brain tumors)
- ☐ ***BCL2* gene rearrangement/translocation t(14;18)**
  (Follicular cell lymphoma)
- ☐ ***BCL6* gene rearrangement**
  (B cell lymphomas)
- ☐ **Chromosome 1p/19q deletion**
  (Oligodendroglioma)
- ☐ ***EGFR* amplification**
  (Glioblastoma and other brain tumors)
- ☐ ***EWS* chromosomal rearrangement/translocation**
  (Ewing's sarcoma/PNET, DSRCT, extraskeletal myxoid chondrosarcoma, and clear cell sarcoma of soft part)
- ☐ ***HER2/ERBB2* amplification**
  (Breast and other solid tumors)
- ☐ ***MDM2* amplification**
  (Soft tissue sarcoma)
- ☐ ***MYC* gene rearrangement/translocation**
  (Burkitt's lymphoma and subset of diffuse large B cell lymphoma)
- ☐ ***SS18 (SYT)* gene rearrangement/translocation t(X;18)**
  (Synovial sarcoma)
- ☐ ***TFE3* gene rearrangement**
  (Renal cell carcinoma)
- ☐ **UroVysion**
  (Urothelial carcinoma)

Clinician Signature: _____

Please forward this form and billing information to: Yale University Medical School Receiving,Yale Molecular Diagnostic Lab - CB557, 200 South Frontage Road, New Haven, CT 06510

Tel 203-785-4492 or 203-737-2533, Fax 203-785-3896

For all medical issues, contact: Pei Hui, MD, PhD, Clinical Director, Molecular Diagnostics Lab, Tel 203-785-6498, Mobile Heartbeat: 475-224-8201

Website: medicine.yale.edu/pathology/clinical/mdx

Rev. 07-19-2024